$25m is an average for Phase 2b .. from my limited research .
IMO there will be some sort of partnership struck before the trials begin .
Shared costs or a licensing deal ??
It may depend on whether they go for a trial with the new approved drugs or have a trial with another trialing drug . MM has said she is thinking of polymerase inhibitors . Vertex's Telaprevir is the only approved polymerase . It has some issues with toxicity and I am thinking they may prefer something like one of Gilead/Pharmasset's new unapproved polys in an interferon free 12 or 24 week trial ( with ribavirin ) .
This would then be likely to include shared costs and it suits the current budget . It also goes along with what MM has alluded to in various updates and reports . IMO it will be 100% effective .
We are then free to capital raise later at a higher price for the co-infected trial ( with int/rib ) and for more working capital .
- Forums
- ASX - By Stock
- BIT
- location/location/location
location/location/location, page-45
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.14M |
Open | High | Low | Value | Volume |
1.9¢ | 2.0¢ | 1.9¢ | $6.369K | 330.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 847148 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.0¢ | 1129029 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 847148 | 0.019 |
10 | 1774771 | 0.018 |
9 | 934388 | 0.017 |
12 | 3734154 | 0.016 |
10 | 1205000 | 0.015 |
Price($) | Vol. | No. |
---|---|---|
0.020 | 1129029 | 5 |
0.021 | 500000 | 1 |
0.022 | 997769 | 4 |
0.023 | 1449422 | 4 |
0.024 | 153949 | 2 |
Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |